Proteasome inhibitors have been actively tested as potential anticancer drugs and in the
treatment of inflammatory and autoimmune diseases. Unfortunately, cells adapt to survive in …

The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the
main protein degradation system in the cell and degrades key mediators of cell growth …

Proteasome inhibition is used therapeutically to induce proteotoxic stress and trigger
apoptosis in cancer cells that are highly dependent on the proteasome. As a mechanism of …

Proteasome machinery is a major proteostasis control system in human cells, actively
compensated upon its inhibition. To understand this compensation, we compared global …

The proteasome degrades most cellular proteins in a controlled and tightly regulated
manner and thereby controls many processes, including cell cycle, transcription, signalling …

As the central figure of the cellular protein degradation machinery, the proteasome is critical
for cell survival. Having been extensively targeted for inhibition, the constitutive proteasome …

Cancer cells show heightened dependency on the proteasome for their survival, growth, and
spread. Proteasome dysregulation is therefore commonly selected in favor of the …

Background Proteasome inhibitors are widely used in the treatment of multiple myeloma and
as research tools. Additionally, diminished proteasome function may contribute to neuronal …

Proteins actively participate in a wide range of cellular physiological functions. But
aggregation of proteins results in cytotoxicity, and unwanted aggregation of misfolded …

The ubiquitin proteasome system (UPS) degrades individual proteins in a highly regulated
fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular …